Vaishnavi Ganti

Vaishnavi Ganti

Gilead Sciences Inc. - California / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 5713111
-
person_outline Vaishnavi Ganti's MOST POPULAR ARTICLES
1-) Preclinical characterization of hpn536, a trispecific, t-cell–activating protein construct for the treatment of mesothelin-expressing solid tumorsME Molloy, RJ Austin, BD Lemon, WH Aaron, V Ganti, A Jones, SD Jones, ...Clinical Cancer Research 27 (5), 1452-1462, 2021302021
2-) Pharmacokinetic application of a bio‐analytical LC‐MS method developed for 5‐fluorouracil and methotrexate in mouse plasma, brain and urineV Ganti, EA Walker, S NagarBiomedical Chromatography 27 (8), 994-1002, 2013282013
3-) First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).JC Bendell, L Fong, MN Stein, TM Beer, A Ross, X Gao, A Weitzman, ...Journal of Clinical Oncology 38 (15_suppl), 5552-5552, 2020172020
4-) Abstract C033: HPN328: An anti-DLL3 T cell engager for treatment of small cell lung cancerWH Aaron, R Austin, M Barath, E Callihan, M Cremin, T Evans, M Gamez, ...Molecular Cancer Therapeutics 18 (12_Supplement), C033-C033, 2019142019
5-) Pharmacokinetic Properties of Humanized IgG1 and IgG4 Antibodies in Preclinical Species: Translational EvaluationM Tabrizi, D Neupane, SE Elie, H Shankaran, V Juan, S Zhang, SC Hseih, ...The AAPS Journal 21, 1-9, 2019112019